Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutSpecial ReportViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Barsha Lal, PhD

Advertisement

Articles by Barsha Lal, PhD

Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting

ARVO 2025: Barsha Lal, PhD, presents an atropine study that addresses families' accomodative concerns

ByHattie Hayes,Martin David Harp,Barsha Lal, PhD
May 7th 2025

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

    1

    FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD

    2

    Neurotrophic keratitis outcomes improve with early, stage-based care

    3

    Improved grading scales for oncology drugs causing ocular adverse events

    4

    Strategic approaches optimize teaching and learning in the clinic

    5

    Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy

    • About
    • Advertise
    • Privacy
    • Editorial Info
    • Editorial Board
    • Terms and Conditions
    • Contact Us
    • Do Not Sell My Personal Information
    • Job Board
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Ophthalmology Times
    • Modern Retina
    • Optometry Times
    • Ophthalmology Times Europe
    EyeCare Network
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us